Jim Simons acquired 1.1M Protalix BioTherapeutics shares worth $2.94M. That's 0.00% of their equity portfolio (1654th largest holding). The investor owns 1.41% of the outstanding Protalix BioTherapeutics stock. The first Protalix BioTherapeutics trade was made in Q4 2019. Since then Jim Simons bought shares fourteen more times and sold shares on eleven occasions. The stake costed the investor $1.83M, netting the investor a gain of 61% so far.